Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey R Chabot

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Biotechnology Progress|October 9, 2007
Analysis of mechanistic pathway models in drug discovery: p38 pathwayBart S Hendriks, Fei Hua, Jeffrey R Chabot
BMC Systems Biology|March 17, 2010
Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitroBart S Hendriks, Kelly M Seidl, Jeffrey R Chabot
Scientific Reports|May 19, 2018
Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody ModalitiesVahid Farrokhi, Jeffrey R Chabot, Hendrik Neubert, et al.
Nature|December 22, 2007
Stochastic gene expression out-of-steady-state in the cyanobacterial circadian clockJeffrey R Chabot, Juan M Pedraza, Prashant Luitel, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 27, 2003
Probing polymerization forces by using actin-propelled lipid vesiclesArpita Upadhyaya, Jeffrey R Chabot, Albina Andreeva, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 19, 2012
Comprehensive mechanism-based antibody pharmacokinetic modelingJeffrey R Chabot, Danielle E Dettling, Paul J Jasper, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|June 6, 2008
Cellular imaging predictions of clinical drug-induced liver injuryJinghai J Xu, Peter V Henstock, Margaret C Dunn, et al.
British Journal of Pharmacology|October 21, 2016
Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlationMengmeng Wang, Amanda K Kussrow, Mireia Fernandez Ocana, et al.
Plos One|March 20, 2015
Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese miceYan Weng, Jeffrey R Chabot, Barbara Bernardo, et al.
Frontiers in Bioinformatics|October 28, 2022
A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody ProgramsGeorgi I Kapitanov, Jeffrey R Chabot, Jatin Narula, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Biotechnology Progress|October 9, 2007
Analysis of mechanistic pathway models in drug discovery: p38 pathwayBart S Hendriks, Fei Hua, Jeffrey R Chabot
BMC Systems Biology|March 17, 2010
Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitroBart S Hendriks, Kelly M Seidl, Jeffrey R Chabot
Scientific Reports|May 19, 2018
Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody ModalitiesVahid Farrokhi, Jeffrey R Chabot, Hendrik Neubert, et al.
Nature|December 22, 2007
Stochastic gene expression out-of-steady-state in the cyanobacterial circadian clockJeffrey R Chabot, Juan M Pedraza, Prashant Luitel, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 27, 2003
Probing polymerization forces by using actin-propelled lipid vesiclesArpita Upadhyaya, Jeffrey R Chabot, Albina Andreeva, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 19, 2012
Comprehensive mechanism-based antibody pharmacokinetic modelingJeffrey R Chabot, Danielle E Dettling, Paul J Jasper, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|June 6, 2008
Cellular imaging predictions of clinical drug-induced liver injuryJinghai J Xu, Peter V Henstock, Margaret C Dunn, et al.
British Journal of Pharmacology|October 21, 2016
Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlationMengmeng Wang, Amanda K Kussrow, Mireia Fernandez Ocana, et al.
Plos One|March 20, 2015
Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese miceYan Weng, Jeffrey R Chabot, Barbara Bernardo, et al.
Frontiers in Bioinformatics|October 28, 2022
A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody ProgramsGeorgi I Kapitanov, Jeffrey R Chabot, Jatin Narula, et al.
Pageof 2